Servier Pharmaceuticals is a U.S. subsidiary of Servier with a focus on oncology treatment and care. See our community guidelines here: https://t.co/atV9J4xxu9

Pharmaceutical

Servier Pharmaceuticals

Christian R. Schubert is the Global Head of External Innovation for Servier R&D and Director of Servier BioInnovation. He is an established leader in external innovation and business development in the biotechnology sector with deep experience in both academic research and commercial business development. 

Prior to joining Servier Group, Christian served as Director of Corporate Strategy Business Development and External Innovation at [Biogen](/org/biogen). He was also Associate Director, Precision Medicine, Human Genetics and Computational Biomedicine at [Pfizer](/org/pfizer), where he helped pioneer the use of human genetics, translational genomics and human biology for the identification and validation of novel targets, biomarkers or patient segmentation strategies to fuel the research and early development portfolio in neuroscience. Further, Christian is an expert in health-related life science innovation and serves as strategic advisor to multiple life science venture funds and startup companies.

Christian received his Bachelor of Science in Biochemistry from University of Munich, with time spent at ETH Zurich and [University of Oxford](/org/university-of-oxford). He also has several postgraduate degrees including a Master of Science in Biochemistry from University of Munich, Doctor of Philosophy from Massachusetts Institute of Technology and a postdoctoral Fellowship from Harvard Medical School.

Christian Schubert

Donna Vieraitis is the Head of Human Resources (HR) at [Servier Pharmaceuticals](/org/servier-pharmaceuticals) with a unique ability to anticipate the needs of an organization in order to prepare for future challenges. In her position, Donna acutely identifies the “people implications” of business strategies and enables alignment of talent against change

A high-energy HR leader, Donna has more than 25 years of success designing and leading critical initiatives that repeatedly enable organizations to respond effectively to the rapidly evolving changes in the global marketplace. She has held various leadership roles at industry-leading companies across diverse industries, including healthcare and technology. Her early career was spent working with organizations such as Intel, McAfee and various tech startups in Silicon Valley where she developed a deep understanding of the business-technology interface while aligning emerging technology needs with services. Most recently, Donna served as Director HR Business Partner at Shire supporting various functions such as the Oncology Business Unit, Finance and Corporate Development before moving to [Servier Pharmaceuticals](/org/servier-pharmaceuticals) to help launch the organization in the United States. 

Donna received her a bachelor’s degree from [Mount Holyoke College](/org/mount-holyoke-college) and a Master of Business Administration from [Babson College](/org/babson-college). 

Donna Vieraitis

Becky Martin is the Head of Medical Affairs at Servier Pharmaceuticals. In this role, Becky is responsible for leading and managing the Medical Affairs team to drive innovation and align commercial and scientific goals.

Becky has a deep passion for the value of medical affairs organizations with more than 25 years of biopharma and pharma experience under her belt. She has extensive experience in strategic design and establishment of fully integrated global medical affairs, HEOR/access, patient services, and Clinical Development functions stemming from previous roles at Bayer, Alkermes, Biogen, NovoNordisk, and EUSA Pharma, among others. She has supported more than 20 product launches across a broad spectrum of therapeutic areas.

Becky holds a mental health-focused clinical degree from NYU where she gained valuable clinic and patient care experiences. In addition, Dr. Martin holds a Master of Science from the University of Pittsburg and a Ph.D. in Industrial and Organizational Psychology from NYU.

Rabecka Martin

Pedro Crisanto is the R&D Chief Operating Officer at Servier Pharmaceuticals. In this role, Pedro leads the R&D managers based in the U.S., promotes the implementation of new ways of working, and leverages local opportunities.

With nearly 20 years of experience, Pedro is a committed leader in the pharmaceutical industry across multiple functions and countries. He began his career at Servier in his home country of Portugal where he supported the launch of the Portuguese Clinical Operations Department. Following this, Pedro held a global role as Deputy Worldwide Clinical Operations Manager at Servier’s headquarters in Paris. During his time in Paris, Pedro supported global initiatives across different structures, countries, and cultures. Prior to joining the U.S.-based office, Pedro spent seven years working as the Director of the International Centre for Therapeutic Research in Australia, New Zealand, Southeast Asia, and India generating successful outcomes in clinical research, company awareness, and external innovation.

Pedro Crisanto

David K. Lee is the CEO of [Servier Pharmaceuticals](/org/servier-pharmaceuticals) and a seasoned veteran of the pharma industry dedicated to bringing innovative, responsible, and life-changing products to patients around the globe. As CEO, David leads [Servier Pharmaceuticals](/org/servier-pharmaceuticals)’ efforts to leverage Servier Group’s global portfolio and seek acquisitions, licensing deals, and partnerships in the United States – a new frontier for the France-based global pharmaceutical company. 

Energized by his long-held mission to find cures for cancer and rare diseases, David spent time early in his career working at Partners in Health in Rwanda, the [World Health Organization](/org/world-health-organization) in Geneva and the Boston Medical Library. While at [Novartis](/org/novartis), he helped launch novel vaccines and orchestrated the successful cross-functional completion of three Phase I trials, two Phase II trials, and a Phase III registration trial. He has a passion for open innovation that feeds his commitment to identifying meaningful partnerships across the healthcare spectrum to foster next-generation scientific discovery that will have a lasting social impact in the United States and, ultimately, around the world.

David received his Bachelor of Science in Biochemistry from [Harvard University](/org/harvard) and later received his Master of Business Administration from [Harvard Business School](/org/harvard-business-school).

David K. Lee

Wendy Poage is the Head of Servier Pharmaceuticals' Patient Office. In her position, Wendy fuels Servier’s efforts toward improving the lives of patients, their families, and caregivers through her management of the Patient Expert Council and tireless efforts to develop patient tools and support services.

Throughout her career, Wendy held leadership positions at several industry-leading companies, including Maximum Medical Solutions, Shire, [Baxalta](/org/baxalta), Global Patient Outcomes, and the Institute for Clinical Research. She has over 20 years of experience working with global patient advocacy and has dedicated her life to helping others and actively supports several non-profit advocacy organizations, including serving as President of the Prostate Conditions Education Council and Administrator of Urologic Oncology at the University of Colorado Health Sciences Center.

Wendy Poage

Susan Pandya is the current head of cancer metabolism at [Servier Pharmaceuticals](/org/servier-pharmaceuticals). Susan has over twenty years of experience in the pharmaceutical industry, specializing in oncology and immuno-oncology. Prior to their current position, they served as vice president of clinical development at [Agios Pharmaceuticals](/org/agios-pharmaceuticals) from 2016 to 2021. From 2012 to 2015, they were the senior director of medical research at [Acceleron Pharma](/org/acceleron-pharma), where they were the medical lead on the development of oncology assets. Susan has also worked as an independent physician reviewer at WorldCare Clinical, LLC and as a consultant editor at DynaMed. In addition to their work in the pharmaceutical industry, they have also served as an instructor in medicine at Harvard Medical School and as the associate director of the experimental therapeutics program at Beth Israel Deaconess Medical Center.

Susan Pandya's educational career began with their earning their high school diploma from Choate Rosemary Hall. Susan then went on to earn their Bachelor of Arts in Physiological Psychology/Psychobiology from [Boston College](/org/boston-college). Finally, they earned their Doctor of Medicine from Tufts University School of Medicine. In addition to their degrees, Susan also has certification from the [American Board of Internal Medicine](/org/american-board-of-internal-medicine) in Hematology, Internal Medicine, and Oncology.

Susan Pandya reports to David K. Lee, CEO. They are on a team with Pedro Crisanto - COO, R&D, Kelly Schlemm - Head, Communications & Public Affairs, and Danielle Button - Head, Finance.

Susan Pandya

Latarsha Stewart is the Head of Compliance and responsible for developing, implementing and maintaining a comprehensive and effective ethics and compliance program for all aspects of Servier business. As chair of the Ethics and Compliance Committee, Latarsha applies her depth of healthcare compliance experience to foster accountability for ethics and compliance throughout all parts of the organization.  

Over the course of her career, Latarsha has developed significant ethics and compliance leadership experience in the oncology pharmaceutical space, with highly developed skills in leadership and cross-functional coordination. As Head of Compliance for the Takeda Global Oncology Business Unit, she was an impactful member of the Global Ethics & Compliance Leadership Team and oversaw the development and implementation of key ethics and compliance initiatives. Latarsha has implemented practical compliance policies and procedures, participated in enterprise risk management, conducted internal auditing, monitoring and investigations and – as a hallmark of her talent and passion – executed exceptionally innovative and effective training on a range of ethics and compliance topics. 

Latarsha received her Bachelor of Science in Communication from [Cornell University](/org/cornell-university). She earned her Juris Doctor and Master of Science degree from [Boston University](/org/boston-university). Latarsha is also a member of the New York Bar.

Latarsha Stewart

Mark Yunger is the Head of Information Technology at [Servier Pharmaceuticals](/org/servier-pharmaceuticals). He works closely with R&D, Technical Operations, Commercial, and Corporate functions. He is responsible for leveraging information technology to accelerate therapies through the pipeline in our pursuit to improve patients' lives. He guides the development and partnering of the company’s digital therapeutics portfolio.

With over 20 years of technology leadership experience within the biotech and high-tech industries, Mark is a proven leader in building world class technology organizations. Prior to [Servier Pharmaceuticals](/org/servier-pharmaceuticals), Mark was Head of Information Technology for [Seres Therapeutics](/org/seres-therapeutics) where he led the building of foundational capabilities to advance microbiome-based products to cure infectious diseases including C. difficile and Ulcerative colitis. Mark was the Vice President of Infrastructure and Operations at [Biogen](/org/biogen) where he led a team of technologists that maintained [Biogen](/org/biogen)’s applications from R&D, to Pharmaceutical Operations and Technology, to Commercial as well as empowered the acceleration of [Biogen](/org/biogen)'s business through designing and building leading-edge cloud services and high performance computing.

Mark received his Bachelor of Science in Psychology from [Western Michigan University](/org/western-michigan-university). He earned his Master of Science in Industrial Organizational Psychology from [Springfield College](/org/springfield-college). He continued his education earning a Doctor of Philosophy in Labor Market and Workforce Development from [Northeastern University](/org/northeastern-university).

Mark Yunger

Bob is the Head of Market Access at [Servier Pharmaceuticals](/org/servier-pharmaceuticals). He is responsible for the market access launch of a new biologic therapy for acute lymphoblastic leukemia, and for all aspects of market access including pricing and contracting, payer value demonstration, health economics and outcomes research, real world evidence strategy, payer engagement and government pricing. In his role, he collaborates on distribution and trade strategy, corporate development, federal and state healthcare policy, compliance and ethics

Bob has significant experience in U.S. and global pricing and market access and has held leadership positions at several life science consulting companies. Bob has held sales and marketing positions at [Johnson & Johnson](/org/johnson-johnson), [Purdue Pharma](/org/purdue-pharma-l-p), and Bristol Myers Squibb. He has experience in launching dozens of biopharmaceutical products in numerous therapeutic areas with specific expertise in Oncology, Hematology and Immunology. For over a decade, Bob was the Founder and President of Evolution Health Initiatives, an industry leading market access consulting and payer communications company. As an industry thought leader, Bob has published several peer-reviewed studies on pricing and market access and has made numerous presentations at congresses in the U.S., Europe, and Asia. 

Bob received his Bachelor of Science in Pharmacy from [Rutgers University](/org/rutgers-university) and a Master of Business Administration from [Fairleigh Dickinson University](/org/fairleigh-dickinson-university).

Robert Paglia

Deniz Razon is the Chief Business Officer at [Servier Pharmaceuticals](/org/servier-pharmaceuticals). In this role, Deniz is responsible for leading strategy development for each therapeutic area, establishing the operational execution of the acquisition process from deal assessment to management, and representing the United States with global business development and licensing colleagues. Further, she is a Board member of [Servier Pharmaceuticals](/org/servier-pharmaceuticals) as well as the Gateway Foundation for Cancer Research.

Over 20 years, Deniz has garnered broad pharmaceutical commercial experience across various therapeutic areas. Prior to joining Servier, Deniz held several roles at Shire including the Vice President of Operations for the Internal Medicine and Oncology franchise and Vice President of United States Sales for Lysosomal Storage Disorders and Oncology. Deniz also spent several years at Baxter and Baxalta where she played a pivotal role in preparing the Oncology franchise for growth through comprehensive analyses of licensing and acquisition opportunities and creating commercialization plans for internal and new partnership assets.

Deniz graduated Magna Cum Laude from [Mount Holyoke College](/org/mount-holyoke-college) with a Bachelor of Arts in International Relations and Economics. She graduated with honors from University of Michigan with her Master of Business Administration in Strategy and Marketing.

Deniz Razon

Eli Taube is the Head of the North America Clinical Operations Hub at [Servier Pharmaceuticals](/org/servier-pharmaceuticals). Eli and his teams in the U.S. and Canada are responsible for the execution of Servier’s clinical studies in North America starting at investigational new drug enabling activities, planning, initiating and conduct of clinical studies, in addition to new drug application (NDA) and biologic licenses applications (BLA) supporting activities. Eli works to drive the team to develop and advance methodologies that will facilitate efficient planning and execution of clinical studies, enabling above benchmark delivery from study concept to NDA/ BLA filing.

Eli has held management positions across biotechnology and pharmaceutical companies including Baxter, [Baxalta](/org/baxalta), Shire and Quintiles (IQVIA). His career is distinguished by a wide range of positions within clinical operation organizations from hands on positions up to therapeutic area team’s management. His mission is to enhance clinical operational teams’ knowledge of the clinical development cascade allowing them to influence all development steps with a focus on study design, regulatory and translational medicine aspects.

Eli received his Bachelor of Science in Biology and Masters of Science in Physiology from the [Tel Aviv University](/org/tel-aviv-university) in Israel.

Eli Taube

Erik Lemay is the Global Head of External Manufacturing for Servier Global and is responsible for the End-to-End delivery of Servier's global portfolio of products that are manufactured at CMO partners. He has 25 years of proven technical operations experience and has developed a strong reputation for managing manufacturing globally and a deep understanding of diversified products and complex manufacturing with a core focus on biologics and vaccines. 

Erik’s experience spans across the manufacturing industry and he has played an instrumental role in the development, manufacturing and life-cycle management of several multi-billion-dollar medicines. Prior to Servier, Erik worked with Bristol Myers Squibb, Bayer Diagnostics and [Pfizer](/org/pfizer) (formerly Wyeth), which included a two-year assignment overseas.

Erik received a Bachelor of Science in Biochemistry from [Ithaca College](/org/ithaca-college) and a Master of Business Administration from [Southern New Hampshire University](/org/southern-new-hampshire-university).

Erik Lemay

Michael J. Bolton serves as [Servier Pharmaceuticals](/org/servier-pharmaceuticals)’ General Counsel. Bringing 25 years of experience with pharmaceuticals law, Michael oversees contracting, governance, and supports the Servier Leadership with legal strategies in the ever-changing oncology space.

Prior to Servier, Michael’s creative problem-solving skills were vital to dealing with pricing and antitrust litigation at [Baxalta](/org/baxalta) and mass tort liability at Baxter Healthcare Corporation. He was also responsible for international coordination of multi-front litigation and partnered with plaintiffs to resolve a U.S. hemophiliac litigation and to support funding for the Ricky Ray Act. Michael’s litigation experience is derived from a major Chicago law firm. He had more than 300 cases sent out to jury trial as a trial supervisor with the City of Chicago Department of Law.

Michael received his bachelor’s degree from the University of Illinois and earned his law degree from the University of Michigan.

Michael Bolton

Sammi Tang is the Head of Biostatistics, Programming and Medical Writing department at [Servier Pharmaceuticals](/org/servier-pharmaceuticals) and a leading expert of biostatistics and bioinformatics in the pharmaceutical industry.

Before joining Servier, Sammi was the Biostatistics Therapeutic Area Head of Oncology, Transplants and Prematurity Neonates at Shire Pharmaceuticals. Prior to that, she worked at [Vertex Pharmaceuticals](/org/vertex-pharmaceuticals), where she led multiple oncology and hematology pipelines. Sammi also worked at  [Amgen](/org/amgen), Mayo Clinical Biostatistics and [Merck](/org/merck). Previously, she served as the biostatistics lead of Companion Diagnostics & Global Statistics Lead for multiple oncology clinical programs from early to late phases at [Amgen](/org/amgen). She is also an active member in American Statistics Association and International Chinese Statistics Association to serve the biostatistics and data science professional community.

Sammi has great experience in CDRH, CBER, CDER, health Canada, EMA and Asian regulatory agencies interactions. She has authored more than 35 articles in peer-reviewed scientific journals on methodology, study design, data analysis and reporting and is a co-inventor of several patents. Besides her daily work, Sammi actively promotes data science through volunteer activities. She is co-founder of a non-profit organization, DahShu, founded to promote research and education in data sciences with almost 5000 members internationally. She also leads teams in the Drug Information Association (DIA) design scientific working group of oncology drug development and small population working group for rare disease statistical methodology development.

Sammi graduated from the University of Michigan Technology University with a Doctor of Philosophy in statistics genetics. 

Rui Tang

Kelly Schlemm is the Head of Communications and Public Affairs at [Servier Pharmaceuticals](/org/servier-pharmaceuticals). Her focus is to devise integrated and aligned communications strategies with the aim of communicating across all stakeholders Servier’s progress, our vision for the future and the roadmap of how we intend to get there. Further, she plays a key role in shaping the company’s policy initiatives in alignment with Corporate Sustainability efforts. She strives daily to meet patient needs and ensure their voice is heard.

Kelly is an executive with wide experience in corporate communications, media relations, investor relations, business development, product and portfolio, brand strategy, crisis communications and public affairs. Kelly previously served as Director of Takeda’s R&D External and Innovation Network Communications. Her career is distinguished by extensive business development and corporate growth experience including leadership roles in the launch and growth of multiple startups from conception to multi-billion-dollar enterprises. She has held management positions across biotechnology and pharmaceutical companies and in communications agencies such as Shire, [Baxalta](/org/baxalta) and [Ogilvy](/org/oglivy).

Kelly received her Bachelor of Arts in Communications from [Seton Hall University](/org/seton-hall-university).

Kelly Schlemm

Arjun Prasad is the Head of Sales & Marketing at [Servier Pharmaceuticals](/org/servier-pharmaceuticals). He is responsible for Sales, Marketing, Analytics, and Operations activities across the portfolio. He leads the teams for ONCASPAR and ASPARLAS in acute lymphoblastic leukemia (ALL) and the teams responsible for TIBSOVO and IDHIFA in mIDH1/2+ acute myeloid leukemias (AML). Arjun’s team is also responsible for U.S. commercialization of future indications.

Arjun has significant experience across a variety of Commercial roles. Prior to joining [Servier Pharmaceuticals](/org/servier-pharmaceuticals), Arjun was at [Agios Pharmaceuticals](/org/agios-pharmaceuticals). He was the Vice President of Global Oncology Marketing, as well as the Vice President of Commercial Operations & Analytics for the Oncology and Genetically Defined Diseases portfolios. Prior to Agios, Arjun spent almost 12 years at [Genentech](/org/genentech), where he led various Sales, Marketing and Analytics teams. Arjun has deep oncology experience, having worked across a number of tumor types, including NSCLC, breast cancer, and melanoma. He has also worked on pipeline and marketed products for a variety of cardiometabolic and immunology indications.  Arjun brings a strong track record of strategic agility and drive for results to his role, as well as a focus on collaboration across programs ranging from early stage development to marketed products.

Arjun maintains a long-standing commitment to addressing unmet needs in healthcare. Early in his career he focused on international public health, working as an International Health Officer with the Office of Global Health Affairs at the U.S. Department of Health & Human Services and also as a Public Health volunteer with the U.S. Peace Corps.  

Arjun  received his Bachelor of Arts from Washington University in St. Louis and a Master in Public Health and Master in Business Administration from Johns Hopkins University.  

Arjun Prasad

Adam Camiel is Chief of Staff for [Servier Pharmaceuticals](/org/servier-pharmaceuticals). He oversees the framework of the organization, identifying and acting upon efficiencies and interdependencies to further the strategic vision for current and future company initiatives. Adam works dynamically as a thought partner to influence outcomes and maintain momentum, adding his unique perspective as a former deal lawyer.

Adam comes to [Servier Pharmaceuticals](/org/servier-pharmaceuticals) from McDermott Will & Emery LLP, where he specialized in life science licensing and collaboration transactions, mergers & acquisitions and healthcare regulatory counsel. Adam’s unique background enabled him to advise a broad scope of pharmaceutical, biotech, and digital health clients. Prior to becoming a corporate lawyer, Adam spent several years at [Novartis](/org/novartis), [Baxalta](/org/baxalta), and Shire leading large cross-functional projects and operations in finance, strategic planning, and marketing capacities.

Adam received his Bachelor of Science from [Babson College](/org/babson-college) and his J.D. and M.B.A. from [Suffolk University](/org/suffolk-university).

Adam Camiel

Danielle Button is the Head of Finance at Servier Pharmaceuticals. In this role, Danielle is responsible for overseeing the financial operations of the company and defining critical initiatives to expand Servier’s business portfolio.

With nearly 25 years of experience, Danielle is a dedicated leader that has held various positions at top pharmaceutical and healthcare companies, including EMD Serono and Patheon. In these roles, she was responsible for the financial direction of the global biologic division as well as several therapeutic areas and portfolio products. She supported global operations, acquisition integrations, strategic decision-making, investments, and much more. Most recently, Danielle served as Vice President, Finance and Procurement, Americas at Stallergenes Greer where she drove their financial and procuring strategy along with supporting metrics, reporting, and action plans. Danielle also worked in the high-tech industry, spending years at Lucent and Parametric Technologies.

Danielle graduated from Babson College with a Bachelor of Science in Entrepreneurship and Marketing and a Master’s Degree in Finance and Accounting.

Servier Pharmaceuticals

Org chart

Teams

Leadership Team

CEO and Executive Team

Discover similar companies